欧林生物股价跌5.05%，富荣基金旗下1只基金重仓，持有1.72万股浮亏损失2.84万元

Group 1 - The core point of the article highlights the recent decline in the stock price of Olin Bio, which fell by 5.05% to 31.02 CNY per share, with a trading volume of 174 million CNY and a turnover rate of 1.35%, resulting in a total market capitalization of 12.592 billion CNY [1] - Olin Bio, established on December 11, 2009, and listed on June 8, 2021, specializes in the research, production, and sales of human vaccines. The main revenue composition includes: 90.99% from adsorbed tetanus vaccine, 4.49% from group A and C meningococcal polysaccharide conjugate vaccine, 3.99% from Haemophilus influenzae type b conjugate vaccine, 0.47% from other (supplementary), and 0.07% from refined tetanus toxin raw liquid [1] Group 2 - From the perspective of major fund holdings, data shows that one fund under Fuyong Fund has a significant position in Olin Bio. The Fuyong Medical Health Mixed Fund A (015655) held 17,200 shares in the first quarter, accounting for 2.06% of the fund's net value, making it the third-largest holding. The estimated floating loss today is approximately 28,400 CNY [2] - The Fuyong Medical Health Mixed Fund A (015655) was established on June 28, 2022, with a latest scale of 11.8186 million CNY. Year-to-date returns are 14.22%, with a one-year return of 10.55%, and a cumulative loss of 20.8% since inception [2]